Protagonist Therapeutics, Inc.’s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues
Despite an already strong run, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) shares have been powering on, with a gain of 51% in the last thirty days. Looking back a bit further, it’s encouraging to see the stock is up 93% in the last year.
After such a large jump in price, Protagonist Therapeutics’ price-to-sales (or “P/S”) ratio of 25.9x might make it look like a strong sell right now compared to other companies in the Biotechs industry in the United States, where around half of the companies have P/S ratios below 10.1x and even P/S below 3x are quite common. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the highly elevated P/S.
